Refractory mucosal candidiasis in advanced human immunodeficiency virus infection

Clinical Infectious Diseases

Volumn 30, Issue 5, 2000, Pages 749-756

  Fichtenbaum, Carl J ^a,g,i,k   Koletar, Susan ^b   Yiannoutsos, Constantin ^c   Holland, Fiona ^c,j,k   Pottage, John ^d,j,k   Cohn, Susan E ^e   Walawander, Ann ^f   Frame, Peter ^g   Feinberg, Judith ^g   Saag, Michael ^h   Van der Horst, Charles ^h   Powderly, W G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ LANCASTER UNIVERSITY   (United Kingdom)

^j Lancaster University ^*

^k VERTEX PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; THRUSH; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; ESOPHAGITIS; FEMALE; FLUCONAZOLE; HUMAN; INCIDENCE; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT FAILURE;

EID: 0033807041     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313765     Document Type: Article

References (37)

1. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency
2. An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction
3. Fluconazole-resistant candida in AIDS
4. Candida albicans resistance in AIDS
5. Fluconazole resistance in AIDS patients
6. Fluconazole-resistant Candida in AIDS
7. Fluconazole-resistant Candida albicans
8. Fluconazole-resistant Candida in AIDS patients
9. Fluconazole-resistant Candida albicans after long-term suppressive therapy
10. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients
11. Fluconazole-resistant candidosis in an HIV cohort
12. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS
13. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
14. Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review
15. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
16. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS
17. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
18. Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidiasis
19. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients
20. Infection due to fluconazole-resistant Candida in AIDS patients: Prevalence and microbiology
21. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
22. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection
23. Refractory and resistant mucosal candidiasis in the acquired immunodeficiency syndrome
24. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy
25. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
26. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients
27. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment and emergence of fluconazole resistance
28. Itraconazole cyclodextrin solution - Effective treatment for HIV-related candidosis unresponsive to other azole therapy
29. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in-vitro susceptibility
30. Itraconazole oral solution for the treatment of fluconazole refractory oropharyngeal candidiasis in HIV-positive patients
31. Long-term safety and efficacy of itraconazole oral solution for the treatment of fluconazole refractory oropharyngeal candidiasis in HIV-positive patients
32. Amphotericin B oral suspension for fluconazole-resistant oral candidiasis in HIV-infected patients
33. Thrush unresponsive to treatment with fluconazole in HIV-infected patients
34. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
35. Correlation between oropharyngeal colonization with Candida and plasma HIV RNA in asymptomatic patients with HIV infection
36. Oral mucosal lesions, CD4 count, viral load and other covariates in women enrolled in the Women's Interagency HIV Study